5-(4-((6-Hydroxy-2,5,7,8-Tetramethylchroman-2-Yl)Methoxy)Benzyl)Thiazolidine-2,4-Dione 5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-四甲基-2H-1-苯并吡喃-2-基)甲氧基]苯基]甲基]-2,4-噻唑烷二酮
CAS 97322-87-7 MFCD00878416
化学结构图
SMILES: CC1=C(O)C(C)=C(C)C2OC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)CCC1=2
化学属性
| Mol. Formula | C24H27NO5S |
|---|---|
| Mol. Weight | 441.54 |
别名和识别编码
| Chemical Name | 5-(4-((6-Hydroxy-2,5,7,8-Tetramethylchroman-2-Yl)Methoxy)Benzyl)Thiazolidine-2,4-Dione |
|---|---|
| CAS Number | 97322-87-7 |
| Synonym | Rezulin Noscal GR 92132X Troglitazone Romglizone (±)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione CS-045 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione Depotox CI 991 CS 045 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione |
| MDL Number | MFCD00878416 |
| PubChem Substance ID | 24724629 |
| Chemical Name Translation | 5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-四甲基-2H-1-苯并吡喃-2-基)甲氧基]苯基]甲基]-2,4-噻唑烷二酮 |
| Beilstein Registry Number | 4338399 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cancer Research, Cell Biology, Cell Signaling and Neuroscience, Gene Regulation, Gene Regulation and Expression, PPAR and RXR Regulators, Pfizer Compounds, T
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Gene Regulation, Gene Regulation and Expression, PPAR and RXR Regulators, Pfizer Compounds, T, 抗肿瘤药物, 生物活性小分子, 癌症研究, 细胞信号转导和神经科学, 细胞生物学
- Sulfur & Selenium Compounds
- Heterocycles
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Aromatics
产品应用
- An oral hypoglycemic agent which improves insulin sensitivity and decreases hepatic glucose production. Antidiabetic.
相关文献及参考
- Ciaraldi, T.P., et al.: Metabolism, 39, 1056 (1990),
- Kuzuya, T., et al.: Diabetes Res. Clin. Pract., 11, 147 (1991),
- Kellerer, M., et al.: Diabetes, 43, 447 (1994),
安全信息
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,953,1995
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,953,1995
TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >300 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #439321
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,953,1995
